EA200000603A1 - Конъюгаты, которые можно использовать при лечении рака предстательной железы - Google Patents

Конъюгаты, которые можно использовать при лечении рака предстательной железы

Info

Publication number
EA200000603A1
EA200000603A1 EA200000603A EA200000603A EA200000603A1 EA 200000603 A1 EA200000603 A1 EA 200000603A1 EA 200000603 A EA200000603 A EA 200000603A EA 200000603 A EA200000603 A EA 200000603A EA 200000603 A1 EA200000603 A1 EA 200000603A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugates
prostate cancer
treating prostate
periwinkle
dtp
Prior art date
Application number
EA200000603A
Other languages
English (en)
Other versions
EA002745B1 (ru
Inventor
Стефен Ф. Брэди
Донг-Мей Фенг
Виктор М. Гарски
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA200000603A1 publication Critical patent/EA200000603A1/ru
Publication of EA002745B1 publication Critical patent/EA002745B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

(57) Раскрыты химические конъюгаты, которые включают олигопептиды, имеющие аминокислотные последовательности, которые избирательно протеолитически расщепляются свободным специфическим антигеном предстательной железы (PSA), и известные цитотоксические средства. Конъюгаты изобретения характеризуются прикреплением расщепляемого олигопептида к атому кислорода в четвертом положении на препарате барвинка, который был дезацетилирован. Такие конъюгаты могут использоваться в лечении рака предстательной железы и доброкачественной гипертрофии предстательной железы (ДТП).Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000603A 1997-12-02 1998-11-25 Конъюгаты, которые можно использовать при лечении рака предстательной железы EA002745B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer
PCT/US1998/025358 WO1999028345A1 (en) 1997-12-02 1998-11-25 Conjugates useful in the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
EA200000603A1 true EA200000603A1 (ru) 2000-12-25
EA002745B1 EA002745B1 (ru) 2002-08-29

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000603A EA002745B1 (ru) 1997-12-02 1998-11-25 Конъюгаты, которые можно использовать при лечении рака предстательной железы

Country Status (26)

Country Link
US (2) US20060148718A1 (ru)
EP (1) EP1036093A1 (ru)
JP (1) JP2001525337A (ru)
KR (1) KR100580137B1 (ru)
CN (1) CN1181092C (ru)
AR (1) AR016427A1 (ru)
AU (1) AU744652B2 (ru)
BG (1) BG65486B1 (ru)
BR (1) BR9815116A (ru)
CA (1) CA2311615A1 (ru)
DZ (1) DZ2665A1 (ru)
EA (1) EA002745B1 (ru)
EE (1) EE200000333A (ru)
HR (1) HRP20000367A2 (ru)
HU (1) HUP0100350A3 (ru)
ID (1) ID24735A (ru)
IL (1) IL136167A0 (ru)
IS (1) IS5502A (ru)
NO (1) NO20002804L (ru)
NZ (1) NZ504615A (ru)
PE (1) PE20000009A1 (ru)
PL (1) PL197006B1 (ru)
SK (1) SK8282000A3 (ru)
TR (1) TR200002260T2 (ru)
TW (1) TW577897B (ru)
WO (1) WO1999028345A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
JP2010536790A (ja) 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9371362B2 (en) * 2012-08-15 2016-06-21 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
WO2014074218A1 (en) * 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
WO2014178839A1 (en) 2013-04-30 2014-11-06 Hewlett-Packard Development Company, L.P. Memory access rate
RS65324B1 (sr) 2013-10-18 2024-04-30 Novartis Ag Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN116635054A (zh) 2020-12-22 2023-08-22 科比欧尔斯公司 包括四肽部分的化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
GR81790B (ru) * 1983-04-29 1984-12-12 Omnichem Sa
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
JP2000506494A (ja) * 1995-10-18 2000-05-30 メルク エンド カンパニー インコーポレーテッド 良性前立腺過形成の治療に有用な複合体
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
WO1998010651A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
CN1284086A (zh) 2001-02-14
US20070021350A1 (en) 2007-01-25
AU1612399A (en) 1999-06-16
NO20002804L (no) 2000-07-21
TR200002260T2 (tr) 2000-12-21
PL197006B1 (pl) 2008-02-29
CA2311615A1 (en) 1999-06-10
AU744652B2 (en) 2002-02-28
NZ504615A (en) 2003-05-30
DZ2665A1 (fr) 2003-03-22
EE200000333A (et) 2001-08-15
KR100580137B1 (ko) 2006-05-16
ID24735A (id) 2000-08-03
HUP0100350A3 (en) 2001-09-28
AR016427A1 (es) 2001-07-04
PE20000009A1 (es) 2000-01-27
BG104563A (en) 2001-04-30
SK8282000A3 (en) 2000-11-07
JP2001525337A (ja) 2001-12-11
BR9815116A (pt) 2000-10-10
CN1181092C (zh) 2004-12-22
US20060148718A1 (en) 2006-07-06
KR20010032687A (ko) 2001-04-25
BG65486B1 (bg) 2008-09-30
PL340768A1 (en) 2001-02-26
WO1999028345A1 (en) 1999-06-10
EP1036093A1 (en) 2000-09-20
NO20002804D0 (no) 2000-05-31
TW577897B (en) 2004-03-01
IS5502A (is) 2000-05-19
IL136167A0 (en) 2001-05-20
HUP0100350A2 (hu) 2001-08-28
EA002745B1 (ru) 2002-08-29
HRP20000367A2 (en) 2000-12-31

Similar Documents

Publication Publication Date Title
EA199900428A1 (ru) Конъюгаты, используемые в лечении рака предстательной железы
EA200000603A1 (ru) Конъюгаты, которые можно использовать при лечении рака предстательной железы
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
DK0771209T3 (da) Hidtil ukendte peptider
EP1009420A4 (en) CONJUGATES WHICH ARE USEFUL IN TREATING PROSTATE CANCER
CY1109614T1 (el) Μορια παρομοια με παραγοντα vii ή viia
NO20020348D0 (no) Peptid acceptor ligeringsmetoder
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
WO2003018611A3 (en) Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
AU4927501A (en) Prostate cancer markers
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
TR200000903T2 (tr) Romatizmal arteritlerin tedavisine yönelik yöntem ve kompozisyonlar.
YU34400A (sh) Konjugati korisni u lečenju kancera prostate
WO2001030804A3 (en) Salt form of a conjugate useful in the treatment of prostate cancer
WO1999044628A8 (en) Conjugates useful in the treatment of prostate cancer
DK0994187T3 (da) Renin-aktivt stof omfattende humant prorenin og antistoffer mod prorenin-profragmentet
WO1993020852A3 (en) Macrocyclic chelating agents, chelates and conjugates thereof
ID28174A (id) Turunan 5-imino-13-deoksi antrasiklin, penggunaannya, dan proses pembuatannya
TH55852A (th) คอนจูเกทมีประโยชน์ในการรักษามะเร็งต่อมลูกหมาก
ECSP972297A (es) Conjugados utiles en el tratamiento de cancer de prostata
TH44562A (th) สารคู่ที่ใช้ในการรักษามะเร็งต่อมลูกหมาก
AU3053100A (en) Pseudopeptide, synthesis method, reagent and applications

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU